A multicenter, single‐arm, open‐label interventional study of adherence to brexpiprazole during switching from previous antipsychotic drugs in patients with schizophrenia or schizoaffective disorder

• Published in: Neuropsychopharmacology reports Vol. 44; no. 1; pp. 187 - 196
• Main Authors: Nakagome, Kazuyuki, Tachimori, Hisateru, Endo, Shiro, Murakami, Ken, Azekawa, Takaharu, Hongo, Seiji, Niidome, Kazunari, Kojima, Yoshitsugu, Yamada, Sakiko, Oi, Hideki, Sumiyoshi, Tomiki
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.03.2024; John Wiley and Sons Inc; Wiley
• Subjects: Agonists; Antipsychotic Agents - therapeutic use; Antipsychotics; Clinical trials; D2 receptor antagonists; Dopamine; dopamine D2 receptor partial agonist; Drug dosages; Drug withdrawal; Electroconvulsive therapy; Humans; Informed consent; medication persistence rate; Olanzapine - therapeutic use; Original; Paliperidone Palmitate - therapeutic use; Psychotic Disorders - drug therapy; Psychotropic drugs; Quinolones - therapeutic use; Risperidone - therapeutic use; safety; Schizoaffective disorder; Schizophrenia; Schizophrenia - drug therapy; Specific Levels of Functioning Scale; Thiophenes - therapeutic use; Well being; Japan; medication persistence rate; Specific Levels of Functioning Scale; D2 receptor antagonists; dopamine D2 receptor partial agonist; safety

The rate of medication persistence was examined in patients with schizophrenia or schizoaffective disorder during switching from previously administered antipsychotics to brexpiprazole, a new dopamine D2 receptor partial agonist. A multicenter, single‐arm, open‐label 24‐week interventional study was...